{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=35", "query": { "condition": "Malignant Melanoma, Metastatic", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 1026, "total_pages": 103, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:56:43.647Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00021164", "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "telomerase: 540-548 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2001-05", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021164" }, { "nct_id": "NCT00003568", "title": "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 9, "location_summary": "Duarte, California • Chicago, Illinois • Maywood, Illinois + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003568" }, { "nct_id": "NCT06743126", "title": "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma, Cutaneous Malignant" ], "interventions": [ { "name": "IMA203", "type": "BIOLOGICAL" }, { "name": "nivolumab plus relatlimab", "type": "BIOLOGICAL" }, { "name": "lifileucel", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "paclitaxel plus carboplatin", "type": "DRUG" }, { "name": "Albumin-Bound Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-01-14", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06743126" }, { "nct_id": "NCT01585415", "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 12, "start_date": "2012-04-09", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585415" }, { "nct_id": "NCT00016055", "title": "Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "lymphokine-activated killer cells", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016055" }, { "nct_id": "NCT06581406", "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "RP2", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 280, "start_date": "2024-12-17", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581406" }, { "nct_id": "NCT00597038", "title": "A Phase I/II Study of Dasatinib and Dacarbazine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Dasatinib and Dacarbazine (DTIC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-11", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-12-16", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 2, "location_summary": "San Francisco, California • Tampa, Florida", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597038" }, { "nct_id": "NCT01584648", "title": "A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trametinib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 423, "start_date": "2012-05-04", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01584648" }, { "nct_id": "NCT02107755", "title": "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Metastases", "Lung Metastases", "Recurrent Melanoma", "Stage IV Melanoma", "Tumors Metastatic to Brain" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "stereotactic radiosurgery", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-09-05", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107755" }, { "nct_id": "NCT01773655", "title": "Clinical and Histopathologic Characteristics of BAP1 Mutations", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Pleural Mesothelioma (MPM)", "Choroidal Nevus", "Primary Uveal Melanoma (UM)", "Metastatic Uveal Melanoma (UM)", "Renal Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "tumor specimens", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2013-01", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-15T18:56:43.647Z", "location_count": 2, "location_summary": "Harrison, New York • New York, New York", "locations": [ { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773655" } ] }